药品GMP指南(2018版 介绍)-PIC‘S

合集下载

PICS对无菌制剂生产GMP的新技术要求

PICS对无菌制剂生产GMP的新技术要求

PIC/S对无菌制剂生产GMP的新技术要求□文/刘知音图/本报记者熊光明编者按:1月21日,本版刊登了PIC/S发布针对GMP无菌要求的解释文件的择要和新文本及其解释部分的译文,引起了业内反响。

今天,本版特邀国家级GMP检查员进一步细致地解释PIC/S对无菌制剂生产GMP的新技术要求。

望能给制药企业更好地理解相关文件助力。

2008年,PIC/S及欧盟均对无菌制剂生产GMP进行了修订,新增或细化了部分技术要求。

为了进一步统一现场检查标准,PIC/S分别于2009年12月1日、2010年1月1日实施了PI032-1和PI032-2,对无菌制剂生产GMP要求的重要变更进行解释说明。

在我国药品GMP规范修订之际,PIC/S的GMP技术要求及说明(以下简称GMP要求)对我国制药行业GMP技术理解和实施,以及GMP检查员现场检查标准把握方面均具有很强的参考价值。

1.洁净区(室)级别划分洁净区(室)洁净级别确认是设施验证的一部分,并需要定期进行再确认。

洁净级别确认和洁净区监测是两个环节,应该明确予以区分并分别进行管理。

洁净级别的确认可以按照ISO14644-1的有关要求实施,确定最少取样点和取样量,同时可以参考ISO14644-1附录中对异常值的相关规定。

我国GMP未对这两个概念进行明确的区分,企业的理解也各不相同,甚至存在个别企业将监测数据统计分析结果作为洁净区回顾验证的情况。

在洁净级别确定中,将A级区5mm粒子的限度从1变更为20(这个变更与我国新版GMP二次征求意见稿的变更是一致的),主要是考虑到检测设备电子噪声、光散射等偏差因素。

按5mm粒子限度标准计量,A级区洁净级别相当于ISO4.8。

D级区没有规定动态的悬浮粒子限度,必要时企业应该根据风险分析结果和历史监测数据,自行建立D级区的动态悬浮粒子限度。

在洁净级别要求中,涉及“动态”和“静态”两个概念,这两个概念虽然不是新出现的,但值得企业和检查员注意的是,企业必须通过SOP对这两个概念进行定义,必要时应根据每个生产操作间的不同要求分别进行定义,在SOP中规定设备的安装状态、运行状态以及人数的限制。

基于《PICS-GMP-缺陷分级指南》的药品生产质量管理规范检查缺陷分级研究

基于《PICS-GMP-缺陷分级指南》的药品生产质量管理规范检查缺陷分级研究

药品生产质量管理规范(GMP)的检查是对药品生产企业进行监督管理的重要手段,国家药品监督管理局已于2021 年9 月正式启动药品检查合作计划(Pharmaceutical Inspection Co-operation Scheme,PIC/S)预加入申请,通过加入PIC/S,借鉴国际管理经验,有助于完善我国药品GMP 标准,改进我国药品GMP 检查体系,推动药品检查员队伍建设,加强国际检查交流合作,促进我国药品监管事业高质量发展[1-2]。

在药品GMP 检查中,缺陷的分级属于检查中最关键的内容之一。

世界卫生组织(WHO)规定现场检查发现严重缺陷时该次检查结论为不通过,发现主要缺陷(6 条以下)时需要基于整改情况确定该次检查结论,当仅发现一般缺陷时该次检查结论为通过[3]。

《PIC/S GMP 缺陷分级指南》是直接影响药品GMP 检查结论的关键性文件,其中许多细节要求值得我国药品检查机构和检查员关注。

检查缺陷的分级直接影响检查的结论和后续进一步的处理方式,因此对PIC/S 药品GMP 检查缺陷分级指南的研究有助于更好地理解国际上关于药品GMP 缺陷分级的标准和尺度。

基于对《PIC/S GMP 缺陷分级指南》的分析,结合国内外GMP 缺陷分级标准规定和具体实践,本文分析了药品GMP 缺陷分级决策流程和风险评估,并进行了药品GMP 缺陷分级示例和案例分析,以促进我国药品GMP 检查进一步与国际接轨。

Part1、《PIC/S GMP 缺陷分级指南》介绍对药品GMP 检查中发现的缺陷进行分级可以形成一个关于被检查企业的客观结论。

统一、协调的缺陷分类系统有助于对不同检查机构和检查员的发现问题结果的比较,也有助于不同的检查机构之间检查报告的比较和交流。

WHO、PIC/S、欧洲药品监督管局和各国药品监督管理机构均建立了GMP 缺陷分级要求,并明确了不同级别缺陷的定义,一般包括严重缺陷(critical deficiency)、主要缺陷(major deficiency)和一般缺陷(minor deficiency/other deficiency,也可称为其他缺陷)。

GMP常见英文缩写

GMP常见英文缩写

GMP英语PIC/S的全称为:Pharmaceutical Inspection Convention/Pharmaceutical Inspection Cooperation Scheme, PIC/S(制药检查草案), 药品检查协会(PIC/S) ,也有人称PIC/S为医药审查会议/合作计划(PIC/S)PIC的权威翻译:药品生产检查相互承认公约API(Active Pharmaceutical Ingredient) 原料药Air Lock 气闸Authorized Person 授权人Batch/Lot 批次Batch Number/Lot-Number 批号;Batch Numbering System 批次编码系统;Batch Records 批记录;Bulk Product 待包装品;Calibration 校正;Clean area洁净区;Consignment (Delivery)托销药品。

FDA(FOOD AND DRUG ADMINISTRATION):(美国)食品药品管理局IND(INVESTIGATIONAL NEW DRUG):临床研究申请(指申报阶段,相对于NDA而言);研究中的新药(指新药开发阶段,相对于新药而言,即临床前研究结束)NDA(NEW DRUG APPLICA TION):新药申请ANDA(ABBREVIATED NEW DRUG APPLICA TION):简化新药申请TREA TMENT IND:研究中的新药用于治疗ABBREVIA TED(NEW)DRUG:简化申请的新药DMF(DRUG MASTER FILE):药物主文件(持有者为谨慎起见而准备的保密资料,可以包括一个或多个人用药物在制备、加工、包装和贮存过程中所涉及的设备、生产过程或物品。

只有在DMF持有者或授权代表以授权书的形式授权给FDA,FDA在审查IND、NDA、ANDA时才能参考其内容)HOLDER:DMF持有者CFR(CODE OF FEDERAL REGULATION):(美国)联邦法规PANEL:专家小组BA TCH PRODUCTION:批量生产;分批生产BA TCH PRODUCTION RECORDS:生产批号记录POST-OR PRE- MARKET SURVEILLANCE:销售前或销售后监督INFORMED CONSENT:知情同意(患者对治疗或受试者对医疗试验了解后表示同意接受治疗或试验)PRESCRIPTION DRUG:处方药OTC DRUG(OVER—THE—COUNTER DRUG):非处方药GMP文件常见缩写ABPI Association of the British Pharmaceutical IndustryADR Adverse Drug ReactionAE Adverse EventAIM Active Ingredient ManufacturerANDA Abbreviated New Drug ApplicationANOVA Analysis of V arianceASM: Active Substance ManufacturerA TC Anatomical Therapeutic ChemicalA TX Animal Test Exemption CertificateBAN British Approved NameBIRA British Institute of Regulatory AffairsBNF British National FormularyBP British PharmacopoeiaC of A Certificate of AnalysisC of S Certificate of SuitabilityCENTRE FOR DRUG EVALUA TION (CDE)Centre for Pharmaceutical Administration (CPA)CMS Concerned Member StateCMS每个成员国COS Certificate of SuitabilityCPMP Committee for Proprietary Medicinal ProductsCRA Clinical Research AssociateCRF Case Report FormCRO Contract Research OrganizationCTA Clinical Trial ApplicationCTC Clinical Trial CertificateCTD Common Technical DocumentCTX Clinical Trials ExemptionDDD Defined Daily DoseDGC Daily Global ComparisonDIA Drug Information AssociationDMF Drug Master FileDrug Registration Branch (DR, Product Evaluation & Registration Division, CPAEDQM (European Directorate for the Quality of Medicines) 欧洲联盟药品质量指导委员会EEA欧洲经济地区EGMA European Generics Medicine AssociationELA Established License ApplicationEMEA European Medicines Evaluation AgencyEMEA(European Agency for the Evaluation of Medicinal Products)欧洲联盟药品评价机构EP European PharmacopoeiaEPAR European Public Assessment ReportsESRA European Society of Regulatory AffairsEuropean Pharmacopoeia Commission 欧洲药典委员会FDAFDA Food and Drug AdministrationFinal Evaluation Report (FER)Free Sale Certificates (FSCs)GCP Good Clinical PracticeGCP药品临床研究管理规范GLP Good Laboratory PracticeGLP 药品临床前安全性研究质量管理规范GMP Good Manufacturing PracticeGMP 药品生产质量管理规范GSP药品销售管理规范Health Sciences Authority (HSA)HSA’s Medicines Advisory Committee (MAC)IB Investigators BrochureICH International Conference for HarmonizationIDMC Independent Data-Monitoring CommitteeIEC Independent Ethics CommitteeIND Investigational New DrugINN International Non-proprietary Name International Conference on Harm onization (ICH) IPC In Process ControlIRB Institutional Review BoardLICENCE HOLDERMA Marketing AuthorizationMAA Marketing Authorization ApplicationMAA上市申请MAH Marketing Authorization HolderMAH 销售许可持有者MCA Medicines Control AgencyMHW Ministry of Health and Welfare (Japan)MR Mutual RecognitionMRA美国与欧盟的互认协议MRAs (Mutual Recognition Agreements) 互相認證同意MRFG Mutual Recognition Facilitation GroupMRP Mutual Recognition ProcedureNAS New Active SubstanceNCE New Chemical EntityNDA New Drug ApplicationNew Chemical Entities (NCEs)New Drug Applications (NDAs)NSAID Non Steroidal Anti Inflammatory Drug NTA Notice To ApplicantsOOS Out of SpecificationOTC Over the CounterPAGB Proprietary Association of Great Britain Ph Eur European PharmacopoeiaPIL Patient Information LeafletPL Product LicensePOM Prescription Only Medicine PRODUCT OWNERPSU Periodic Safety UpdatesQA Quality AssuranceQC Quality ControlRAJ Regulatory Affairs JournalRMS Reference Member StateRMS相互认可另一成员国RSD Relative Standard DeviationRx Prescription OnlySAE Serious Adverse EventSMF Site Master FileSOP Standard Operating ProcedureSOP (STANDARD OPERA TION PROCEDURE)标准运作程序SPC Summary of Product CharacteristicsTherapeutic Goods Administration (TGA)USP US PharmacopoeiaVMF V eterinary Master FileVPC V eterinary Products CommitteeA.A.A Addition and Amendments 增补和修订AC Air Conditioner 空调器ADR Adverse Drug Reaction 药物不良反应AFDO Association of Food and Drug Officials 食品与药品官员协会(美国)ACC Accept 接受AQL Acceptable Quality Level 合格质量标准ADNA Abbreviated New Drug Application 简化的新药申请BOM Bill of Material 物料清单BPC Bulk pharmaceutical Chemicals 原料药CBER Center for Biologics Evaluation Research 生物制品评价与研究中心CFU Colony Forming Unit 菌落形成单位DMF Drug Master File 药品管理档案CDER Center for Drug Evaluation and Research 药物评价与研究中心CI Corporate Identity (Image) 企业识别(形象)CIP Cleaning in Place 在线清洗CSI Consumer Safety Inspector 消费者安全调查员CLP Cleaning Line Procedure 在线清洗程序DAL Defect Action Level 缺陷作用水平DEA Drug Enforcement Administration 管制药品管理DS Documentation System 文件系统FDA Food and Drug Administration 食品与药品管理局(美国)GATT General Agreement on Tariffs and Trade 关贸总协会GMP Good Manufacturing Practice 药品生质量管理规范GCP Good Clinical Practice 药品临床实验管理规范GLP Good Laboratory Practice 实验室管理规范GSP Good Supply Practice 药品商业质量规范GRP Good Retail Practice 药品零售业质量管理规范GAP Good Agriculture Practice 药材生产管理规范GVP Good V alidation Practice 验证管理规范GUP Good Use Practice 药品使用规范HVAC Heating V entilation Air Conditioning 空调净化系统ISO International Organization for Standardization 国际标准化组织MOU Memorandum of Understanding 谅解备忘录PF Production File 生产记录用表格OTC Over the Counter (Drug) 非处方药品PLA Product License Application 产品许可申请QA Quality Assurance 质量保证QC Quality Control 质量控制QMP Quality Management Procedure 质量管理程序SDA State Drug Administration 国家药品监督管理局SMP Standard Management Procedure 标准管理程序SOP Standard Operating Procedure 标准操作程序TQC Total Quality Control 全面质量管理USA United States Pharmacopoeia 美国药典。

药品GMP指南 版 介绍 PIC‘S

药品GMP指南 版 介绍 PIC‘S

PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEMEPE 009-14 (Intro) 1 July 2018GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS© PIC/S July 2018 Reproduction prohibited for commercial purposes.Reproduction for internal use is authorised, provided that the source is acknowledged.Editor:PIC/S Secretariat 14 rue du Roveray CH-1207 Genevae-mail: info@ web site: PE 009-14 (Intro)1 July 2018IntroductionINTRODUCTIONGeneralIn order to further facilitate the removal of barriers to trade in medicinal products, to promote uniformity in licensing decisions and to ensure the maintaining of high standards of quality assurance in the development, manufacture and control of medicinal products, the following Guide to Good Manufacturing Practice for Medicinal Products and its Annexes has been adopted.The standards set out herein apply to medicines and similar products intended for human use. It is recommended, however, that the same kind of attention be given to the manufacture of veterinary products. Administrative measures of national health authorities should be directed towards the application of these standards in practice, and any new or amended national regulations for good manufacturing practice should at least meet their level. These standards are also intended to serve manufacturers as a basis for the elaboration of specific rules adapted to their individual needs.It is recognised that there are acceptable methods, other than those described in this Guide, which are capable of achieving the principles of the Guide. This Guide is not intended to place any restraint upon the development of new concepts or new technologies, which have been validated and provide a level of Quality Assurance at least equivalent to those set out in this Guide.The Guide is divided into two parts and a number of annexes which are common to both parts. Part I covers GMP principles for the manufacture of medicinal products. Part II covers GMP for active substances used as starting materials. The annexes provide detail on specific areas of activity. For some manufacturing processes, different annexes will apply simultaneously (e.g. annex on sterile preparations and on radiopharmaceuticals and/or on biological medicinal products). A glossary of some terms used in the Guide has been incorporated after the annexes. A specific glossary for APIs can be found at the end of Part II.HistoryPart I of the PIC/S GMP GuideOriginally, the PIC/S GMP Guide (“PIC Basic Standards” of 1972) derives from the WHO GMP Guide and was further developed in order to comply with stringent manufacturing and health requirements in PIC/S countries, to cover new areas (e.g. biologicals, radiopharmaceuticals, etc.) and to adapt to scientific and industrial technology (e.g. biotech, parametric release etc.). The aim of such improvements was to ensure that high quality medicines were produced in line with the PIC Convention and then the PIC Scheme.In 1989, the EU adopted its own GMP Guide, which – in terms of GMP requirements – was equivalent to the PIC/S GMP Guide. Since that time, the EU and the PIC/S GMP Guides have been developed in parallel and whenever a change has been made to one, the other has been amended so that both Guides are practically identical.PE 009-14 (Intro)1 July 2018IntroductionThere are, however, some differences between the two Guides. These differences are the following: the definition of Pharmaceutical Product (referred to as “Medicinal Product” in this Guide), which is found in Article 1 of the Pharmaceutical Inspection Convention, has been retained; references to the EU Directives, as well as to MRAs, have been deleted; the expression “authorised person” (see Glossary) is used in the PIC/S Guidewhile the expression “Qualified Person” is used in the EU Guide; since not all Participating Authorities under the PIC Scheme are parties to theEuropean Pharmacopoeia Convention, the mention of “European Pharmacopoeia” in the Guide has been amended to read “European or other relevant Pharmacopoeia”.Part II of the PIC/S GMP GuideOn 22 May 2001, the PIC/S Committee adopted the “Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients” (ICH Q7A) developed by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) as a stand-alone guide (PE 007). It is recalled that the first draft of this GMP Guide for APIs was elaborated by PIC/S, before it was transferred to ICH. At its Düsseldorf meeting on 29-30 May 2006, the PIC/S Committee decided to make it Part II of the current Guide.ADOPTION AND ENTRY INTO FORCEAdoption by the Committee of PE 009-14 Entry into force of PE 009-1417-18 April 2018 1 July 2018REVISION HISTORYDate 21 December 200010 August 2001Version NumberReasons for revisionPH 1/97 (Rev.) Revision of Annex 14 Renumbering of all annexes Change in the editor’s address andinsertion of copyright statement Inclusion of revision historyPH 1/97 (Rev. 2) Amendment of para. 42 of Annex 1 Revision of Annex 6 New Annex 15 New Annex 17 Amendment to the glossaryPE 009-14 (Intro)1 July 2018Introduction15 January 20021 September 2003 1 July 2004 1 January 2006 1 June 2006 1 August 2006 5 April 20071 September 200715 January 20091 September 2009 1 January 2013 1 March 2014 1 October 2015 1 January 2017 1 July 2018PH 1/97 (Rev. 3)PE 009-1 PE 009-2 PE 009-3 PE 009-4 PE 009-5 PE 009-6PE 009-7PE 009-8PE 009-9 PE 009-10 PE 009-11 PE 009-12 PE 009-13 PE 009-14 New Annex 4 New Annex 5 Reference to Annex 18 of EC GMPGuide Amendment of Annex 1 (mainlysection 3) Revision of Annex 13 Change in the Editor’s co-ordinates Revision of Chapter 1 Revision of Chapter 6 Corrections to revision of Chapter 6 Revision of Chapter 8 Reorganisation of the PIC/S GMP Guide in Part I, Part II and Annexes Incorporation of PE 007 (APIs guide) as Part II New Annex 19 Revision of the Introduction Change in the Editor’s co-ordinates Revision of General Introduction(“History”) and Introduction to Part II Deletion of footnotes in Chapter 6(Part I) and Annex 13 Revision of Chapter 1 (Part I) Revision of Annex 1 New Annex 20 Revision of Annex 3 Revision of Chapter 4 (Part I) Revision of Annex 6, 7, 11 and 13 Introduction of QRM principals inPIC/S GMP Guide – Part II Revision of Annex 2 and 14 Revision of Annex 15 Revision of Chapters 1, 2, 6 & 7 (Part I) Revision of Chapters 3, 5 & 8 (Part I) Revision of Annex 17PE 009-14 (Intro)1 July 2018。

国际GMP认证与PIC-S介绍

国际GMP认证与PIC-S介绍

[转载]国际GMP认证与PIC/S简介提要:中国药品制剂出口的瓶颈在于国际认证,药品制剂要想进入国际主流市场,首先要过认证关。

本文简要地介绍了国际认证组织之一的国际医药品检查协约计划(PIC/S)及其GMP认证覆盖的国家,介绍PIC/S-GMP,和进行GMP认证之前的《制药工厂基本资料编写指南(Site Master File)》。

并通过介绍台湾如何普及PIC/S-GMP认证,以为我国制药企业提升GMP水平与国际出轨提供借鉴。

PIC/S简介:国际药品监查合作计划(The Pharmaceutical Inspection Co-operation Scheme, 简称PIC/S )成立于1995年11月,为世界上唯一的由各国GMP检查权责机关组成的国际合作组织,成立的宗旨为了消除药品贸易中的障碍,提高药品获取许可的一致性,确保药品质量,促进国际GMP法规标准之协和及GMP检查质量的一致化。

PIC/S现有33个会员分属32个国家,如澳大利亚、奥地利、比利时、加拿大、捷克、丹麦、芬兰、法国、德国、希腊、匈牙利、冰岛、爱尔兰、意大利、拉脱维亚、列支敦士登、马来西亚、荷兰、挪威、波兰、葡萄牙、罗马尼亚、新加坡、斯洛伐克、西班牙、瑞典、瑞士和英国等等。

该组织在全球享有较高声誉,其内部检查官均来自各成员国的相关专业权威人士,同时身兼参与的官方(监管机构)的代表。

组织内会员国拥有一致的GMP规范与检查系统,且相互承认检查結果,该组织颁发的GMP证书在PIC/S组织成员国之间相互认可,通过某一成员国的PIC/S-GMP认证也就意味着跨进了32个国家的第一道门槛,所以,是进入国际市场的快捷通道之一。

PIC/S前身则为创立于1970年的「Pharmaceutical Inspection Convention,简称PIC」,PIC的组织章程不同于PIC/S,PIC为一个以国家为会员单位共同签署成立的正式国际组织,该组织直运作到1995年欧盟成立时,PIC受限于欧盟体制而无法与其它想加入的国家签署协议,因而衍生出另一个非正式、更有弹性的国际合作组织——PIC/S。

国际GMP认证与PIC-S介绍1

国际GMP认证与PIC-S介绍1

[转载]国际GMP认证与PIC/S简介提要:中国药品制剂出口的瓶颈在于国际认证,药品制剂要想进入国际主流市场,首先要过认证关。

本文简要地介绍了国际认证组织之一的国际医药品检查协约计划(PIC/S)及其GMP认证覆盖的国家,介绍PIC/S-GMP,和进行GMP认证之前的《制药工厂基本资料编写指南(Site Master File)》。

并通过介绍台湾如何普及PIC/S-GMP认证,以为我国制药企业提升GMP水平与国际出轨提供借鉴。

PIC/S简介:国际药品监查合作计划(The Pharmaceutical Inspection Co-operation Scheme, 简称PIC/S )成立于1995年11月,为世界上唯一的由各国GMP检查权责机关组成的国际合作组织,成立的宗旨为了消除药品贸易中的障碍,提高药品获取许可的一致性,确保药品质量,促进国际GMP法规标准之协和及GMP检查质量的一致化。

PIC/S现有33个会员分属32个国家,如澳大利亚、奥地利、比利时、加拿大、捷克、丹麦、芬兰、法国、德国、希腊、匈牙利、冰岛、爱尔兰、意大利、拉脱维亚、列支敦士登、马来西亚、荷兰、挪威、波兰、葡萄牙、罗马尼亚、新加坡、斯洛伐克、西班牙、瑞典、瑞士和英国等等。

该组织在全球享有较高声誉,其内部检查官均来自各成员国的相关专业权威人士,同时身兼参与的官方(监管机构)的代表。

组织内会员国拥有一致的GMP 规范与检查系统,且相互承认检查結果,该组织颁发的GMP证书在PIC/S组织成员国之间相互认可,通过某一成员国的PIC/S-GMP认证也就意味着跨进了32个国家的第一道门槛,所以,是进入国际市场的快捷通道之一。

PIC/S前身则为创立于1970年的「Pharmaceutical Inspection Convention,简称PIC」,PIC的组织章程不同于PIC/S,PIC为一个以国家为会员单位共同签署成立的正式国际组织,该组织直运作到1995年欧盟成立时,PIC受限于欧盟体制而无法与其它想加入的国家签署协议,因而衍生出另一个非正式、更有弹性的国际合作组织——PIC/S。

PICS GMP中文版(第一部分)

PICS GMP中文版(第一部分)

1.3
當開發新的製藥品質系統或修改既有的 系統時,應考慮公司的規模與複雜性。 系統的設計應納入適當的風險管理原 則,包含適當工具的使用在內。雖然系 統的某些層面是涵蓋全公司的,而其他 層面是製藥場所專一的,但製藥品質系 統的有效性通常是在製藥場所層級加以 證明之。
1.3
The size and complexity of the company’s activities should be taken into consideration when developing a new Pharmaceutical Quality System or modifying an existing one. The design of the system should incorporate appropriate risk management principles including the use of appropriate tools. While some aspects of the system can be company-wide and others site-specific, the effectiveness of the system is normally demonstrated at the site level.
1
製藥品質系統 1(PHARMACEUTICAL QUALITY SYSTEM 1)
1
製造廠須建立並執行有效的「製藥品質保證系
National requirements require to establish and
統」 。 「製藥品質系統」一詞用於本章係與 ICH Q10 術語一致,為了本章的目的,此等術語可視為可互 換的。

为什么要加入PICS

为什么要加入PICS

近日,NMPA官宣成为药品检查合作计划(PIC/S)正式申请者,我国药品制造的国际化脚步又迈出了坚实的一步。

一直以来,国内药企想要实现药品出口就难免要重新设计改造GMP厂房车间,同时还要承担高额的资质维护费,以及所在国派遣检察员的现场检查费用,费时费钱费力。

随着PIC/S确认国家药监局的正式申请者身份,无疑将助力解决上述问题,实现药品国际化的“最后一公里”。

1、加入PIC/S,国家局早已筹划。

PIC/S(PharmaceuticalInspectionCooperationScheme),即药品检查合作计划。

该组织的前身是1970年欧洲自由贸易联盟(EFTA)成立的PIC,目的是为了消除国与国之间的贸易壁垒,实现GMP互认。

当前,已有>50个国家和地区的药监机构成为PIC/S成员,如FDA、PMDA、TGA、MHRA等;同时,WHO、EMA等均为PIC/S的合作组织。

加入PIC/S,分两步:1)预加入申请,最长期限2年,该阶段PIC/S 会对申请机构的药品检查体系进行评估。

2)正式申请,最快1.5年,最慢6年,该阶段PIC/S需要进行系统、全面的评估工作。

评估过程中,审计清单设定11个模块对整个检查体系进行评估,范围涵盖法规、GMP标准、检查程序等。

模块项下,再细分亚指标,以及对应的重要程度、评估方式等。

由上述加入PIC/S程序可知,NMPA 本次“正式申请”,是在已经取得了部分成绩的基础上,而更进一步的工作,时间上至少应该是在1-2年以前。

但,实际上对于加入PIC/S这件事,从国家药监局网站搜索可知,早在十余年前,就已经考虑这件事了。

如早在2008年,国家局曾邀请美国FDA、欧盟EMEA、WHO、PIC/S以及相关协会等,就实施药品GMP的先进经验、药品GMP发展趋势及相关的法律法规等进行交流与研讨;2012年,药品安全监管司发布《境外药品生产企业检查管理办法》征求意见,其中现场主文件内容的具体要求按照PIC/S关于现场主文件的最新要求撰写。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEMEPE 009-14 (Intro) 1 July 2018GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS© PIC/S July 2018 Reproduction prohibited for commercial purposes. Reproduction for internal use is authorised, provided that the source is acknowledged.Editor:PIC/S Secretariat 14 rue du Roveray CH-1207 Genevainfo@ e-mail: web site:PE 009-14 (Intro)1 July 2018IntroductionINTRODUCTIONGeneral In order to further facilitate the removal of barriers to trade in medicinal products, to promote uniformity in licensing decisions and to ensure the maintaining of high standards of quality assurance in the development, manufacture and control of medicinal products, the following Guide to Good Manufacturing Practice for Medicinal Products and its Annexes has been adopted. The standards set out herein apply to medicines and similar products intended for human use. It is recommended, however, that the same kind of attention be given to the manufacture of veterinary products. Administrative measures of national health authorities should be directed towards the application of these standards in practice, and any new or amended national regulations for good manufacturing practice should at least meet their level. These standards are also intended to serve manufacturers as a basis for the elaboration of specific rules adapted to their individual needs. It is recognised that there are acceptable methods, other than those described in this Guide, which are capable of achieving the principles of the Guide. This Guide is not intended to place any restraint upon the development of new concepts or new technologies, which have been validated and provide a level of Quality Assurance at least equivalent to those set out in this Guide. The Guide is divided into two parts and a number of annexes which are common to both parts. Part I covers GMP principles for the manufacture of medicinal products. Part II covers GMP for active substances used as starting materials. The annexes provide detail on specific areas of activity. For some manufacturing processes, different annexes will apply simultaneously (e.g. annex on sterile preparations and on radiopharmaceuticals and/or on biological medicinal products). A glossary of some terms used in the Guide has been incorporated after the annexes. A specific glossary for APIs can be found at the end of Part II. History Part I of the PIC/S GMP Guide Originally, the PIC/S GMP Guide (“PIC Basic Standards” of 1972) derives from the WHO GMP Guide and was further developed in order to comply with stringent manufacturing and health requirements in PIC/S countries, to cover new areas (e.g. biologicals, radiopharmaceuticals, etc.) and to adapt to scientific and industrial technology (e.g. biotech, parametric release etc.). The aim of such improvements was to ensure that high quality medicines were produced in line with the PIC Convention and then the PIC Scheme. In 1989, the EU adopted its own GMP Guide, which – in terms of GMP requirements – was equivalent to the PIC/S GMP Guide. Since that time, the EU and the PIC/S GMP Guides have been developed in parallel and whenever a change has been made to one, the other has been amended so that both Guides are practically identical.PE 009-14 (Intro)1 July 2018Introduction There are, however, some differences between the two Guides. differences are the following:  Thesethe definition of Pharmaceutical Product (referred to as “Medicinal Product” in this Guide), which is found in Article 1 of the Pharmaceutical Inspection Convention, has been retained; references to the EU Directives, as well as to MRAs, have been deleted; the expression “authorised person” (see Glossary) is used in the PIC/S Guide while the expression “Qualified Person” is used in the EU Guide; since not all Participating Authorities under the PIC Scheme are parties to the European Pharmacopoeia Convention, the mention of “European Pharmacopoeia” in the Guide has been amended to read “European or other relevant Pharmacopoeia”.  Part II of the PIC/S GMP Guide On 22 May 2001, the PIC/S Committee adopted the “Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients” (ICH Q7A) developed by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) as a stand-alone guide (PE 007). It is recalled that the first draft of this GMP Guide for APIs was elaborated by PIC/S, before it was transferred to ICH. At its Düsseldorf meeting on 29-30 May 2006, the PIC/S Committee decided to make it Part II of the current Guide.ADOPTION AND ENTRY INTO FORCEAdoption by the Committee of PE 009-14 Entry into force of PE 009-14 17-18 April 2018 1 July 2018REVISION HISTORYDate 21 December 2000 Version Number PH 1/97 (Rev.)     10 August 2001 PH 1/97 (Rev. 2)      Reasons for revision Revision of Annex 14 Renumbering of all annexes Change in the editor’s address and insertion of copyright statement Inclusion of revision history Amendment of para. 42 of Annex 1 Revision of Annex 6 New Annex 15 New Annex 17 Amendment to the glossaryPE 009-14 (Intro)1 July 2018Introduction                  15 January 2009 PE 009-8    15 January 2002PH 1/97 (Rev. 3)1 September 2003 1 July 2004 1 January 2006 1 June 2006 1 August 2006 5 April 2007PE 009-1 PE 009-2 PE 009-3 PE 009-4 PE 009-5 PE 009-6New Annex 4 New Annex 5 Reference to Annex 18 of EC GMP Guide Amendment of Annex 1 (mainly section 3) Revision of Annex 13 Change in the Editor’s co-ordinates Revision of Chapter 1 Revision of Chapter 6 Corrections to revision of Chapter 6 Revision of Chapter 8 Reorganisation of the PIC/S GMP Guide in Part I, Part II and Annexes Incorporation of PE 007 (APIs guide) as Part II New Annex 19 Revision of the Introduction Change in the Editor’s co-ordinates Revision of General Introduction (“History”) and Introduction to Part II Deletion of footnotes in Chapter 6 (Part I) and Annex 13 Revision of Chapter 1 (Part I) Revision of Annex 1 New Annex 20 Revision of Annex 31 September 2007PE 009-71 September 2009 1 January 2013 1 March 2014PE 009-9 PE 009-10 PE 009-111 October 2015 1 January 2017 1 July 2018PE 009-12 PE 009-13 PE 009-14 Revision of Chapter 4 (Part I)  Revision of Annex 6, 7, 11 and 13  Introduction of QRM principals in PIC/S GMP Guide – Part II  Revision of Annex 2 and 14  Revision of Annex 15  Revision of Chapters 1, 2, 6 & 7 (Part I)  Revision of Chapters 3, 5 & 8 (Part I)  Revision of Annex 17PE 009-14 (Intro)1 July 2018。

相关文档
最新文档